User login
Moderate Exercise Can Reduce Colon Polyps by One-Third
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
FROM THE ANNUAL DIGESTIVE DISEASE WEEK
Moderate Exercise Can Reduce Colon Polyps by One-Third
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
In a prospective study of multiple ethnic groups, people with at least 1 hour of moderate physical activity per week had a one-third lower risk of colon polyps.
"One thing that was new and exciting about our research was that the ethnic diversity in our population was different" from that of other studies, Dr. Nelson Sanchez of Memorial Sloan-Kettering Cancer Center, New York, said during a press conference in advance of the annual Digestive Disease Week. The findings were presented at the meeting on May 8.
Of the 982 middle-aged adults who enrolled in the study, 558 (57%) were Hispanic, 202 (21%) were Asian, 149 (15%) were black, and 69 (7%) were white. A total of 603 participants (61%) had a body mass index that was categorized as overweight or obese (25 kg/m2 or greater).
The participants all had average risk for colorectal cancer, and the polyps were identified during screening colonoscopy. The overall prevalence of colon polyps was 29.5%, but the prevalence was significantly higher among patients who reported less than 1 hour per week of exercise, compared with those who reported exercising for 1 hour or more (33.2% vs. 25.3%, respectively); this difference was statistically significant (P = .008).
About half of the participants (513 individuals, or 52%) reported that they exercise for at least 1 hour per week, and the median duration of this activity level was 5 years (range, 1.5-10 years).
In addition, the researchers looked at risk for adenomas, which can be precursors of colorectal cancer, particularly if they are advanced adenomas. Those participants who exercised for 1 or more hours weekly had an adenoma prevalence of 14%, compared with 19% in those who exercised less than 1 hour a week, said Dr. Sanchez.
Also, overweight and obese patients who exercised at least 1 hour per week were 40% less likely to have any adenomas, and 63% less likely to have advanced adenomas than were overweight or obese individuals who exercised less, the researchers noted.
When the data were analyzed by race/ethnicity, the odds of having advanced adenomas greater than 1 cm in size or having colorectal cancers were lowest for blacks who exercised for at least 1 hour each week (odds ratio, 0.16). In addition, the odds ratio for adenomas was cut in half (0.47) for Hispanics who exercised for at least 1 hour each week, compared with Hispanics who exercised less.
These results could have a substantial public health impact, as they suggest that even a moderate level of exercise may reduce polyp risk in a diverse population, said Dr. Sanchez. "Even low levels of physical activity have been shown to confer protective benefits," he noted.
The next steps for researchers include identifying which specific physical activities and what level of intensity convey the most protection from colon polyps, Dr. Sanchez added.
Dr. Sanchez said he had no financial conflicts to disclose.
FROM THE ANNUAL DIGESTIVE DISEASE WEEK
Major Finding: Prevalence of polyps was significantly higher among patients who reported less
than 1 hour per week of exercise, compared with those who reported
exercising for 1 hour or more (33.2% vs. 25.3%).
Data Source: A prospective study of 982 middle-aged adults, all with an average risk for colorectal cancer.
Disclosures: Dr. Sanchez said he had no financial conflicts to disclose
Obesity Screening of Younger Children Leads to Better BMI, Lipids
Intensive lifestyle intervention after obesity screening significantly improved body mass index z scores in children aged 2-5 years, compared with children aged 6-21 years, based on data from 462 children enrolled in a tertiary-care clinical obesity program.
"Children 2 to 5 years old responded nearly seven times more favorably than [did] older children aged 6 to 21 years old after completion of 6 months within our obesity program," Dr. Carl A. Sather of Indiana University, Indianapolis, said in a press conference. The complete study findings will be presented on May 9 at the annual Digestive Disease Week.
The findings contrast with the current U.S. Preventive Services Task Force guidelines, which suggest screening children aged 6-18 years (not younger) for obesity and referring them for comprehensive therapy if needed, he said.
The study population included 44 children aged 2-5 years and 418 children and adolescents aged 6-21 years. All participants were referred to the program and had a body mass index above the 95th percentile for age and sex, or had a BMI greater than the 85th percentile with comorbidities.
During the lifestyle intervention, changes in BMI z scores were significantly greater in the younger group, compared with the older group after 3 months (–0.23 vs. –0.05) and after 6 months (–0.64 vs. –0.094).
The 12-month program began with a 3-month clinic-based intervention that included sessions with a dietitian, physical therapist, child psychologist, and pediatrician. Children and their caregivers were taught behavior change techniques including goal setting, accountability, self-monitoring, and stimulus control.
The children and caregivers met in group sessions once a month during months 4-6 and bimonthly during months 7-12. Interventions included the use of a food journal and a pedometer. Program completion rates were similar between the younger and older groups at 3 months (43% vs. 44%) and 6 months (11% vs. 14%).
The mean age of the younger patients was 4.6 years, with a mean BMI z score at baseline of 3.46. The mean age of the older patients was 12.2 years, with a mean BMI z score at baseline of 2.55.
The baseline rate of dyslipidemia (HDL cholesterol less than 40 mg/dL) was similar in the younger vs. older groups (56% vs. 59%, respectively), and the baseline rate of transaminitis, or elevated levels of aspartate transaminase and alanine transaminase, also was similar for the two groups (7% vs. 7.5%, respectively). Follow-up lab testing for dyslipidemia at 6-12 months showed similar gains in HDL in both the younger and older groups (increases of 2.84 mg/dL vs. 2.00 mg/dL, respectively).
Although the findings suggest that obesity screening is appropriate for preschoolers, it is important for the parent or caregiver to monitor the use of pedometers and food/activity journals by the youngest children, Dr. Sather noted in an interview.
"We had to take some specific strategies to address developmental limitations in the 2- to 3-year-old group," he said. But pedometers can be used by children if they are monitored by adults, and the food and activity journal also can be used easily by young children with adult supervision, he said.
"We don’t see any reason that younger children should be excluded from behavioral interventions [for obesity]" said Dr. Sather. "Although our numbers are small, our completion rate is consistent with other centers," he said, and the data are sufficiently convincing to recommend that all children aged 2-18 years should receive obesity screening, similar to the American Academy of Pediatrics’ current recommendations. "We hope that our data will prompt some further research and examine the positive impacts of BMI screening at younger ages, and that it will contribute to stronger conclusions and healthier pediatric populations," he said.
Dr. Sather said he had no financial conflicts to disclose.
Intensive lifestyle intervention after obesity screening significantly improved body mass index z scores in children aged 2-5 years, compared with children aged 6-21 years, based on data from 462 children enrolled in a tertiary-care clinical obesity program.
"Children 2 to 5 years old responded nearly seven times more favorably than [did] older children aged 6 to 21 years old after completion of 6 months within our obesity program," Dr. Carl A. Sather of Indiana University, Indianapolis, said in a press conference. The complete study findings will be presented on May 9 at the annual Digestive Disease Week.
The findings contrast with the current U.S. Preventive Services Task Force guidelines, which suggest screening children aged 6-18 years (not younger) for obesity and referring them for comprehensive therapy if needed, he said.
The study population included 44 children aged 2-5 years and 418 children and adolescents aged 6-21 years. All participants were referred to the program and had a body mass index above the 95th percentile for age and sex, or had a BMI greater than the 85th percentile with comorbidities.
During the lifestyle intervention, changes in BMI z scores were significantly greater in the younger group, compared with the older group after 3 months (–0.23 vs. –0.05) and after 6 months (–0.64 vs. –0.094).
The 12-month program began with a 3-month clinic-based intervention that included sessions with a dietitian, physical therapist, child psychologist, and pediatrician. Children and their caregivers were taught behavior change techniques including goal setting, accountability, self-monitoring, and stimulus control.
The children and caregivers met in group sessions once a month during months 4-6 and bimonthly during months 7-12. Interventions included the use of a food journal and a pedometer. Program completion rates were similar between the younger and older groups at 3 months (43% vs. 44%) and 6 months (11% vs. 14%).
The mean age of the younger patients was 4.6 years, with a mean BMI z score at baseline of 3.46. The mean age of the older patients was 12.2 years, with a mean BMI z score at baseline of 2.55.
The baseline rate of dyslipidemia (HDL cholesterol less than 40 mg/dL) was similar in the younger vs. older groups (56% vs. 59%, respectively), and the baseline rate of transaminitis, or elevated levels of aspartate transaminase and alanine transaminase, also was similar for the two groups (7% vs. 7.5%, respectively). Follow-up lab testing for dyslipidemia at 6-12 months showed similar gains in HDL in both the younger and older groups (increases of 2.84 mg/dL vs. 2.00 mg/dL, respectively).
Although the findings suggest that obesity screening is appropriate for preschoolers, it is important for the parent or caregiver to monitor the use of pedometers and food/activity journals by the youngest children, Dr. Sather noted in an interview.
"We had to take some specific strategies to address developmental limitations in the 2- to 3-year-old group," he said. But pedometers can be used by children if they are monitored by adults, and the food and activity journal also can be used easily by young children with adult supervision, he said.
"We don’t see any reason that younger children should be excluded from behavioral interventions [for obesity]" said Dr. Sather. "Although our numbers are small, our completion rate is consistent with other centers," he said, and the data are sufficiently convincing to recommend that all children aged 2-18 years should receive obesity screening, similar to the American Academy of Pediatrics’ current recommendations. "We hope that our data will prompt some further research and examine the positive impacts of BMI screening at younger ages, and that it will contribute to stronger conclusions and healthier pediatric populations," he said.
Dr. Sather said he had no financial conflicts to disclose.
Intensive lifestyle intervention after obesity screening significantly improved body mass index z scores in children aged 2-5 years, compared with children aged 6-21 years, based on data from 462 children enrolled in a tertiary-care clinical obesity program.
"Children 2 to 5 years old responded nearly seven times more favorably than [did] older children aged 6 to 21 years old after completion of 6 months within our obesity program," Dr. Carl A. Sather of Indiana University, Indianapolis, said in a press conference. The complete study findings will be presented on May 9 at the annual Digestive Disease Week.
The findings contrast with the current U.S. Preventive Services Task Force guidelines, which suggest screening children aged 6-18 years (not younger) for obesity and referring them for comprehensive therapy if needed, he said.
The study population included 44 children aged 2-5 years and 418 children and adolescents aged 6-21 years. All participants were referred to the program and had a body mass index above the 95th percentile for age and sex, or had a BMI greater than the 85th percentile with comorbidities.
During the lifestyle intervention, changes in BMI z scores were significantly greater in the younger group, compared with the older group after 3 months (–0.23 vs. –0.05) and after 6 months (–0.64 vs. –0.094).
The 12-month program began with a 3-month clinic-based intervention that included sessions with a dietitian, physical therapist, child psychologist, and pediatrician. Children and their caregivers were taught behavior change techniques including goal setting, accountability, self-monitoring, and stimulus control.
The children and caregivers met in group sessions once a month during months 4-6 and bimonthly during months 7-12. Interventions included the use of a food journal and a pedometer. Program completion rates were similar between the younger and older groups at 3 months (43% vs. 44%) and 6 months (11% vs. 14%).
The mean age of the younger patients was 4.6 years, with a mean BMI z score at baseline of 3.46. The mean age of the older patients was 12.2 years, with a mean BMI z score at baseline of 2.55.
The baseline rate of dyslipidemia (HDL cholesterol less than 40 mg/dL) was similar in the younger vs. older groups (56% vs. 59%, respectively), and the baseline rate of transaminitis, or elevated levels of aspartate transaminase and alanine transaminase, also was similar for the two groups (7% vs. 7.5%, respectively). Follow-up lab testing for dyslipidemia at 6-12 months showed similar gains in HDL in both the younger and older groups (increases of 2.84 mg/dL vs. 2.00 mg/dL, respectively).
Although the findings suggest that obesity screening is appropriate for preschoolers, it is important for the parent or caregiver to monitor the use of pedometers and food/activity journals by the youngest children, Dr. Sather noted in an interview.
"We had to take some specific strategies to address developmental limitations in the 2- to 3-year-old group," he said. But pedometers can be used by children if they are monitored by adults, and the food and activity journal also can be used easily by young children with adult supervision, he said.
"We don’t see any reason that younger children should be excluded from behavioral interventions [for obesity]" said Dr. Sather. "Although our numbers are small, our completion rate is consistent with other centers," he said, and the data are sufficiently convincing to recommend that all children aged 2-18 years should receive obesity screening, similar to the American Academy of Pediatrics’ current recommendations. "We hope that our data will prompt some further research and examine the positive impacts of BMI screening at younger ages, and that it will contribute to stronger conclusions and healthier pediatric populations," he said.
Dr. Sather said he had no financial conflicts to disclose.
FROM DIGESTIVE DISEASE WEEK
Major Finding: Lifestyle intervention after obesity screening led to significantly greater reductions in body mass index among children aged 2-5 years, compared to children aged 6-21 years.
Data Source: Data from 462 obese children aged 2-21 years.
Disclosures: Dr. Sather said he had no financial conflicts to disclose.
Type 2 Diabetes Patients on Medication Report High Rates of Hypoglycemia
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Major Finding: Among type 2 diabetes patients taking insulin, 40%-43% reported having an episode of hypoglycemia in the past month, regardless of whether they took oral antidiabetes medications.
Data Source: A survey of 2,801 adults who had been treated for type 2 diabetes for at least 12 months.
Disclosures: The study was supported by AstraZeneca.
Type 2 Diabetes Patients on Medication Report High Rates of Hypoglycemia
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Type 2 Diabetes Patients on Medication Report High Rates of Hypoglycemia
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
SAN DIEGO – Regardless of whether they take oral diabetes medications, roughly 40%-43% of type 2 diabetes patients who took insulin reported having hypoglycemia in the past month, according to survey findings from 2,801 adults.
"Hypoglycemia is a leading limiting factor in the glycemic management of adults with type 2 diabetes mellitus who are treated with insulin or a sulfonylurea agent," Dr. Andrew Green said at the annual meeting of the American Association of Clinical Endocrinologists. The findings suggest a need to consider the risk of hypoglycemia as part of a risk-versus-benefit analysis when designing a treatment regimen for type 2 diabetes patients, he added.
Of the survey respondents who received oral medications, 52% reported receiving sulfonylureas. And among those patients using sulfonylureas for the past 12 months, significantly more of them reported having hypoglycemia during the past month than did those who did not receive sulfonylureas (28% vs. 19%).
The 5-year population-based survey, known as the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD) was initiated in 2005.
Overall, 1,793 patients (64%) received oral medication only, 221 (8%) received insulin only, 361 (13%) received both types of therapy, and 426 (15%) were not receiving any diabetes treatment at the time of the survey. The average ages of the patients in group ranged from 61 to 65 years; more than 70% of the patients in each group were white, and more than half (58%-64%) were women, said Dr. Green, an endocrinologist in Overland Park, Kansas.
Patients who received both insulin and oral medications were significantly more likely to be younger and obese compared with those who received either type of treatment alone.
The study was limited by the use of self-reports and the lack of data on the severity and causes of hypoglycemia.
The study was supported by AstraZeneca.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Major Finding: Among type 2 diabetes patients taking insulin, 40%-43% reported having an episode of hypoglycemia in the past month, regardless of whether they took oral antidiabetes medications.
Data Source: A survey of 2,801 adults who had been treated for type 2 diabetes for at least 12 months.
Disclosures: The study was supported by AstraZeneca.
Primary Hyperparathyroidism Presentation Varies With Age
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Major Finding:At presentation, 58% of patients with primary hyperparathyroidism who were younger than age 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years. Data Source: A consecutive review of 335 patients undergoing parathyroidectomy. Disclosures: Dr. Cherenfant had no financial conflicts to disclose.
Primary Hyperparathyroidism Presentation Varies With Age
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
SAN DIEGO – Contrary to conventional wisdom, primary hyperparathyroidism is not extremely rare among people younger than 30 years, and it presents differently in these patients, compared with those older than 60 years, according to an analysis of data from 335 consecutive patients.
"Since routine calcium screening is not done in younger patients, primary hyperparathyroidism should be considered when nephrolithiasis, GERD [gastroesophageal reflux disease], and bone disease occur in patients younger than 30 years," Dr. Jovenel Cherenfant of the University of Chicago and his colleagues concluded.
To identify differences in hyperparathyroidism among age groups, the researchers reviewed data from 335 consecutive patients who underwent parathyroidectomy at a single center between 1998 and 2009.
The study population included 40 patients younger than 30 years, 155 patients aged 30-60 years, and 140 patients older than 60 years. Approximately 63% were women.
Prior to surgery, calcium and parathyroid hormone levels were significantly higher in patients younger than 30 years, compared with those older than 60 years. Presurgical calcium levels in patients younger than 30 years and those older than 60 years were 11.7 mg/dL and 10.9 mg/dL, respectively. Presurgical parathyroid hormone levels for the older and younger groups were 290 pg/mL and 159 pg/mL, respectively. All levels returned to normal after surgery; the median postoperative calcium and intact parathyroid hormone values for all patients were 9.35 mg/dL and 42.1 pg/mL, respectively, according to the results, which were presented in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
At presentation, 58% of patients younger than 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years.
After the researchers controlled for age, women had a higher prevalence of GERD and osteoporosis, compared with men. Men of all ages were more likely to have a history of kidney stones, compared with women, but kidney stones were more common in younger women, compared with older women (40% of women younger than 30 years vs. 12% of women older than 30 years).
In addition, osteoporosis was significantly more common in patients older than 60 years vs. those younger than 30 years (49% vs. 9%), but 63% of the younger women had osteopenia, vs. 43% of those older than 60 years.
Dr. Cherenfant had no financial conflicts to disclose.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Major Finding:At presentation, 58% of patients with primary hyperparathyroidism who were younger than age 30 years complained of GERD, compared with 26% of those aged 30-60 years and 23% of those older than 60 years. Data Source: A consecutive review of 335 patients undergoing parathyroidectomy. Disclosures: Dr. Cherenfant had no financial conflicts to disclose.
Linagliptin Improves Glycemic Control Independent of BMI
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
Body text goes here
Doctor’s Bio
Body text goes here
Doctor’s Bio
Body text goes here
Doctor’s Bio
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Major Finding: Text.
Data Source: Text.
Disclosures: Text.
Linagliptin Improves Glycemic Control Independent of BMI
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
SAN DIEGO – Type 2 diabetes patients treated with linagliptin showed statistically significant improvements in hemoglobin A1c level after 24 weeks, regardless of their body mass index, on the basis of data from a pooled analysis of 2,224 patients.
Linagliptin, a dipeptidyl peptidase–4 (DPP-4) inhibitor, was approved by the U.S. Food and Drug Administration on May 2 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Two other DPP-4 inhibitors have been previously approved for the same indication – sitagliptin (Januvia) and saxagliptin (Onglyza).
In three phase III, randomized, double-blind, placebo-controlled trials, the primary efficacy outcome was the change in HbA1c level from baseline to 24 weeks. The average reduction in HbA1c was similar between BMI groups: –0.79 for those with a BMI less than 25 kg/m2, –0.57 for those with a BMI of 25-30, and –0.62 for those with a BMI above 30, Dr. Angelina Trujillo of Boehringer Ingelheim Pharmaceuticals in Ridgefield, Conn., reported in a poster at the annual meeting of the American Association of Clinical Endocrinologists.
One study evaluated linagliptin as monotherapy in patients previously untreated with oral diabetes medications or taking a single nonthiazolidinedione medication. The second study evaluated linagliptin when added to metformin in patients whose diabetes was not well controlled, some of whom were taking one additional oral antidiabetic medication. The third study evaluated linagliptin as additional therapy for patients whose diabetes was not well controlled on both metformin and a sulfonylurea.
The mean age of the patients ranged from 55 to 58 years, and about half were women. The average BMI ranged from 23 to 34 kg/m2.
The overall rate of adverse events was similar among the three groups, Dr. Trujillo and her associates found. In particular, the overall incidence of hyperglycemia was lower in the linagliptin group, compared with the placebo group, across all BMI categories. A higher incidence of hypoglycemia in the linagliptin group compared with the placebo group was seen in the linagliptin patients who were taking both metformin and a sulfonylurea.
"This was expected, as previously described in the literature, due to the combination with a sulfonylurea," she wrote in the poster. "The overall hypoglycemic event rate with linagliptin in monotherapy and add-on to metformin therapy was very low (less than 1.0%)," she added.
The incidence of serious adverse events based on BMI categories in the linagliptin and placebo groups were 4% and 5%, respectively, in those with BMIs of less than 25 kg/m2; 3% and 4% in those with BMIs of 25-30 kg/m2; and 3% and 2% in those with BMIs above 30.
"The safety and tolerability of linagliptin was comparable to placebo across baseline categories of normal, overweight, and obese BMI in this pooled analysis," she reported.
Litagliptin will be marketed as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly. The study was supported by Boehringer Ingelheim Pharmaceuticals.
FROM THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS